CN101816703A - Medicinal composition for treating cardiac, cerebral and vascular diseases and preparation method thereof - Google Patents
Medicinal composition for treating cardiac, cerebral and vascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN101816703A CN101816703A CN200910219409A CN200910219409A CN101816703A CN 101816703 A CN101816703 A CN 101816703A CN 200910219409 A CN200910219409 A CN 200910219409A CN 200910219409 A CN200910219409 A CN 200910219409A CN 101816703 A CN101816703 A CN 101816703A
- Authority
- CN
- China
- Prior art keywords
- ischemic
- cerebral
- water
- cardiovasculars
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to a compound preparation of Chinese medicament and chemical medicament, in particular to a medicinal composition for treating cardiac, cerebral and vascular diseases and a preparation method thereof. The Chinese medicament is prepared by mixing an extractive prepared by performing water extraction on astragalus and root of red-rooted salvia by an appropriate method, ligustrazine hydrochloride and suitable auxiliary materials. The medicinal composition is used for treating occlusive cerebrovascular diseases, such as cerebral insufficiency, cerebral thrombosis, cerebral embolism and other ischemic cardiovascular diseases, such as chest distress, angina, myocardial infarction, ischemic stroke, thromboangiitis obliterans and other symptoms of coronary artery disease. The medicinal composition has reasonable composition and remarkable and stable treatment effect.
Description
Technical field: the present invention relates to the compound preparation of a kind of Chinese medicine and chemical medicine, promptly treat pharmaceutical composition of cardiovascular and cerebrovascular disease and preparation method thereof.
Background technology: existing red-rooted-salvia-root chuanxiong-rhizome azine injecta, be used for obliterated cerebral vascular disease, as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism and other ischemic cardiovasculars, as diseases such as uncomfortable in chest, the angina pectoris of coronary heart disease, myocardial infarction, cerebral infarction, thromboangiitis obliteranss.Owing to be subjected to the restriction of existing Chinese medicine technology of preparing and the complexity of Chinese medicine ingredients, Chinese medicine is easy to generate acute allergic reaction and other burst untoward reaction, and certain potential safety hazard is arranged clinically.The pathogenic principle of cardiovascular and cerebrovascular disease is comparatively complicated, but the patient mostly is the old people, and its pathogenesis is mainly " blood stasis due to qi deficiency ".Prior art lacks the QI invigorating composition.While injection manufacturing cost height, inconvenience such as transportation, also inapplicable home-use.
Summary of the invention: the present invention is directed to above-mentioned deficiency, a kind of reasonable recipe and uncomplicated is provided in conjunction with Chinese medical theory, treatment obliterated cerebral vascular disease evident in efficacy, as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism and other ischemic cardiovasculars, as the medicine and the preparation method of diseases such as uncomfortable in chest, the angina pectoris of coronary heart disease, myocardial infarction, cerebral infarction, thromboangiitis obliterans.
Technical solution of the present invention is: be used for obliterated cerebral vascular disease, as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism and other ischemic cardiovasculars, medicine as diseases such as uncomfortable in chest, the angina pectoris of coronary heart disease, myocardial infarction, cerebral infarction, thromboangiitis obliteranss is characterized in that it is prepared from by the following raw materials in weight material: 333 parts of the Radixs Astragali, 333 parts of Radix Salviae Miltiorrhizaes, 33.3 parts of ligustrazine hydrochloride.Preferably make tablet.Each medicinal ingredient also can be mixed and made into common dosage forms in the pharmacy such as dispersible tablet, oral cavity disintegration tablet, capsule, drop pill, pill, oral liquid, mixture, syrup or granule with pharmaceutical carrier or additive.
Preparation method: the Radix Astragali decocts with water 2 times, adds for the first time 10 times of amounts of water and decocts 2 hours, adds 8 times of amounts of water the 2nd time to decoct 1 hour, and collecting decoction filters, and is evaporated to thick paste, and drying is ground into fine powder; Radix Salviae Miltiorrhizae decocts with water twice, adds for the first time 10 times of amounts of water and decocts 2 hours, adds 8 times of amounts of water the 2nd time to decoct 1 hour, and collecting decoction filters, and is evaporated to thick paste, and drying is ground into fine powder; Get the above-mentioned two kinds of fine powders of ligustrazine hydrochloride and merge, cross 80 mesh sieves, mixing, the system granule, tabletting, coating, promptly.
Function cures mainly: be used for obliterated cerebral vascular disease, as cerebral blood supply insufficiency, cerebral thrombosis, cerebral embolism and other ischemic cardiovasculars, as diseases such as uncomfortable in chest, the angina pectoris of coronary heart disease, myocardial infarction, cerebral infarction, thromboangiitis obliteranss.
Usage and dosage: with the tablet is example, oral, one time 3,2 times on the one.
Advantage of the present invention is: 1, increase Chinese medicine astragalus simply on original technology prescription basis, increased gas compensation function, to meet the Chinese medical theory of " the capable then blood of gas is capable, and the stagnation of QI is blood clotting then ", make the prescription combination more reasonable, curative effect is more remarkable.2, the water soluble ingredient of the Radix Astragali and Radix Salviae Miltiorrhizae all is an effective ingredient, all adopts decocting, and fries in shallow oil respectively and carry 2 times, and effective ingredient leaches fully.3, be developed to oral formulations after, drug administration is convenient and safe, toxic and side effects is little, low cost of manufacture is applicable to that family uses, and can enriches clinical use dosage form.
The present invention shows to have antiplatelet aggregation through pharmacodynamics test, expansion small artery, blood viscosity lowering, quicken erythrocytic flow velocity, microcirculation improvement, effects such as blood circulation promoting and blood stasis dispelling, and accumulative platelet had depolymerisation, and have and resist myocardial ischemia and the effect of myocardial infarction.Through clinical verification, determined curative effect is significantly stable, does not see tangible untoward reaction, is to the effective prescription because of verification.
Specific implementation method: embodiment 1: the red ligustrazine sheet of stilbene: Radix Astragali 333g, Radix Salviae Miltiorrhizae 333g, ligustrazine hydrochloride 33.3g, make 1000.
Embodiment 2: preparation method: raw material: Radix Astragali 333g, Radix Salviae Miltiorrhizae 333g, ligustrazine hydrochloride 33.3g.The Radix Astragali decocts with water 2 times, adds for the first time 10 times of amounts of water and decocts 2 hours, adds 8 times of amounts of water the 2nd time to decoct 1 hour, and collecting decoction filters, and is evaporated to thick paste, and drying is ground into fine powder; Radix Salviae Miltiorrhizae decocts with water and adds for the first time 10 times of amounts of water twice and decocted 2 hours, adds 8 times of amounts of water and decocts collecting decoction 1 hour for the 2nd time, filter, being evaporated to relative density is 1.30-1.35 (50 ℃), drying, be ground into fine powder, get ligustrazine hydrochloride and mix, add right amount of auxiliary materials again with above-mentioned two kinds of fine powders, cross 80 mesh sieves, mixing is made granule with 75-85% ethanol, drying, arrangement adds lubricant, mix thoroughly, tabletting, coating, packing are promptly.
Claims (6)
1. medicine for the treatment of obliterated cerebral vascular disease and other ischemic cardiovasculars.It is characterized in that it is prepared from by the following raw materials in weight material: 100 parts-600 parts of the Radixs Astragali, 100 parts-600 parts of Radix Salviae Miltiorrhizaes, 10 parts-50 parts of ligustrazine hydrochloride.
2. according to the medicine of the described treatment obliterated cerebral vascular disease of claim 1 and other ischemic cardiovasculars, it is characterized in that: ligustrazine hydrochloride is replaced with ligustrazine phosphate or other ligustrazine derivants.
3. according to the medicine of the described treatment obliterated cerebral vascular disease of claim 1 and other ischemic cardiovasculars, it is characterized in that its dosage form is a tablet.
4. according to the medicine of the described treatment obliterated cerebral vascular disease of claim 3 and other ischemic cardiovasculars, it is characterized in that the Radix Astragali wherein is 333g, Radix Salviae Miltiorrhizae 333g, ligustrazine hydrochloride 33.3g, and its above-mentioned consumption is the consumption of 1000 of preparations.
5. according to the medicine of the described treatment obliterated cerebral vascular disease of claim 1 and other ischemic cardiovasculars, it is characterized in that its dosage form is dispersible tablet, oral cavity disintegration tablet, capsule, drop pill, pill, oral liquid, mixture, syrup or granule.
6. the preparation method of the medicine of the described treatment obliterated cerebral vascular disease of claim 3 and other ischemic cardiovasculars, it is characterized in that method for making is as follows: the Radix Astragali decocts with water 2 times, adding for the first time 10 times of amounts of water decocted 2 hours, adding 8 times of amounts of water for the 2nd time decocted 1 hour, collecting decoction filters, and is evaporated to thick paste, drying is ground into fine powder; Radix Salviae Miltiorrhizae decocts with water twice, adds for the first time 10 times of amounts of water and decocts 2 hours, adds 8 times of amounts of water the 2nd time to decoct 1 hour, and collecting decoction filters, and is evaporated to thick paste, and drying is ground into fine powder; Get ligustrazine hydrochloride and above-mentioned two kinds of fine powders merging, cross 80 mesh sieves, mixing, the system granule, tabletting, coating, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910219409A CN101816703A (en) | 2009-12-09 | 2009-12-09 | Medicinal composition for treating cardiac, cerebral and vascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910219409A CN101816703A (en) | 2009-12-09 | 2009-12-09 | Medicinal composition for treating cardiac, cerebral and vascular diseases and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101816703A true CN101816703A (en) | 2010-09-01 |
Family
ID=42652080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910219409A Pending CN101816703A (en) | 2009-12-09 | 2009-12-09 | Medicinal composition for treating cardiac, cerebral and vascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101816703A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526174A (en) * | 2012-03-13 | 2012-07-04 | 山东仁和堂药业有限公司 | Isosorbide mononitrate and preparation technology thereof |
| CN103877461A (en) * | 2014-03-07 | 2014-06-25 | 赵艳清 | Yang-warming and qi-benefiting electuary for myocardial ischemia and preparation method thereof |
| CN104383178A (en) * | 2014-11-21 | 2015-03-04 | 张家港市中医医院 | Traditional Chinese medicine composition for treating cardio-cerebrovascular disease as well as preparation and preparation method of traditional Chinese medicine composition |
| CN108888656A (en) * | 2018-09-18 | 2018-11-27 | 山东科迪臻药业有限公司 | A kind of pharmaceutical composition and the preparation method and application thereof for treating inflammation infection disease and/or cardiovascular and cerebrovascular disease |
| CN113197947A (en) * | 2021-05-19 | 2021-08-03 | 一力制药(罗定)有限公司 | Composition for clearing and activating channels and collaterals and dredging blood vessels and preparation method thereof |
-
2009
- 2009-12-09 CN CN200910219409A patent/CN101816703A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102526174A (en) * | 2012-03-13 | 2012-07-04 | 山东仁和堂药业有限公司 | Isosorbide mononitrate and preparation technology thereof |
| CN102526174B (en) * | 2012-03-13 | 2013-12-25 | 山东仁和堂药业有限公司 | Isosorbide mononitrate and preparation technology thereof |
| CN103877461A (en) * | 2014-03-07 | 2014-06-25 | 赵艳清 | Yang-warming and qi-benefiting electuary for myocardial ischemia and preparation method thereof |
| CN104383178A (en) * | 2014-11-21 | 2015-03-04 | 张家港市中医医院 | Traditional Chinese medicine composition for treating cardio-cerebrovascular disease as well as preparation and preparation method of traditional Chinese medicine composition |
| CN104383178B (en) * | 2014-11-21 | 2018-08-24 | 张家港市中医医院 | A kind of Chinese medicine composition that treating cardiovascular and cerebrovascular disease and its preparation and preparation method |
| CN108888656A (en) * | 2018-09-18 | 2018-11-27 | 山东科迪臻药业有限公司 | A kind of pharmaceutical composition and the preparation method and application thereof for treating inflammation infection disease and/or cardiovascular and cerebrovascular disease |
| CN113197947A (en) * | 2021-05-19 | 2021-08-03 | 一力制药(罗定)有限公司 | Composition for clearing and activating channels and collaterals and dredging blood vessels and preparation method thereof |
| CN113197947B (en) * | 2021-05-19 | 2023-01-13 | 一力制药(罗定)有限公司 | Composition for clearing and activating channels and collaterals and dredging blood vessels and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101816703A (en) | Medicinal composition for treating cardiac, cerebral and vascular diseases and preparation method thereof | |
| CN101002856A (en) | Medicine for treating and preventing cardiovascular and cerebrovascular diseases, and its preparing method | |
| CN108261505A (en) | A kind of drug of logical stalkization bolt and preparation method thereof | |
| CN101791332B (en) | Compound gingko health product solid preparation | |
| CN101129469B (en) | Traditional Chinese medicine composition for preventing and controlling cardiovascular disease | |
| CN102293985B (en) | Traditional Chinese medicine composition used for treating coronary heart disease and preparation method thereof | |
| CN102657754B (en) | Thrombus collaterals-dredging medicament | |
| CN101766666A (en) | Chinese medicament for treating cardiovascular and cerebrovascular diseases | |
| CN101618131A (en) | Chinese medicinal compound preparation for treating coronary heart disease and angina | |
| CN103055201A (en) | Chinese medicinal herb composition for treating coronary heart disease and preparation method thereof | |
| CN104784402A (en) | Traditional Chinese medicine for treating cerebral arteriosclerosis | |
| CN110638879A (en) | Composition for treating chronic heart failure and preparation method thereof | |
| CN103181962A (en) | Traditional Chinese medicine effervescence particles for treating apoplexy sequela, and preparation method thereof | |
| CN104758835B (en) | A kind of Chinese medicine being used for the treatment of cerebral infarction disease | |
| CN103735879A (en) | Traditional Chinese medicine decoction for treating carotid artery plaque | |
| CN102526412A (en) | Chinese medicine composition for treating myocardial infarction | |
| CN100441181C (en) | Method for preparing micropill capsule of salvia miltiorrhiza bge, and gynostemma pentaphyllum, and its use | |
| CN100594914C (en) | Medicine for curing coronary heart disease | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN103191210B (en) | Traditional Chinese medicine for treating coronary heart diseases | |
| CN103656012A (en) | Formula of drug for treating coronary heart disease and angina pectoris and application of formula | |
| CN101357221A (en) | Traditional Chinese medicine preparation for treating female coldness | |
| CN103239620B (en) | Traditional Chinese medicine for treating qi-deficiency heart diseases | |
| CN103202992B (en) | Medicine for treating cardiac enlargement | |
| CN100348233C (en) | Preparation method of Chinese medicinal composition for treating allodromy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100901 |